Alkermes Says Johnson & Johnson Will Not Pursue Further Development of Four-week Risperidone

Reuters -- Units of Johnson & Johnson have decided not to pursue further development of a four-week long-acting version of antipsychotic drug risperidone, Alkermes Inc said in a regulatory filing on Wednesday.